Pluristem’s stem cell therapy looks promising in Phase I

Backed by the promising outcome of an early-stage study of its stem cell therapy for improving arterial blood flow, Israel's Pluristem Technology is laying the groundwork for a Phase II now scheduled to launch next year. In a small study of 21 patients with critical limb ischemia, PLX-PAD sailed through without any serious side effects reported. There were no negative immune responses registered and half of the 12 patients tested at a three-month follow-up demonstrated improvements in two of...